Font Size: a A A

Research On The Regulation Mechanism Of Ca_V1.2 C Hannel By CaM And CaMK? In Pathological Myocardial Hypertrophy

Posted on:2021-02-13Degree:MasterType:Thesis
Country:ChinaCandidate:S Q WangFull Text:PDF
GTID:2404330611491694Subject:Pharmaceutical
Abstract/Summary:PDF Full Text Request
Background:In the face of various cardiovascular stimuli,the heart will undergo an adaptive compensatory response-myocardial hypertrophy to maintain early cardiac output.However,if the heart is under stress for a long time,it may lead to pathological myocardial hypertrophy and may develop into diseases such as heart failure and sudden death.Pathological myocardial hypertrophy has become an independent risk factor for cardiovascular disease.Pathological myocardial hypertrophy has the characteristics of continuous progress and difficult to reverse,but the mechanism of difficult to reverse is still unclear.The change of calcium homeostasis in myocardial cells has a very important effect on the occurrence of myocardial hypertrophy,and Ca2+mainly enters myocardial cells through CaV1.2channels.Therefore,it is important to study the changes of CaV1.2 function during pathologicalmyocardialhypertrophy.Calmodulin?Ca M?and Ca2+/calmodulin-dependent protein kinase ??CaMK??can regulate the intracellular calcium content by regulating the function of CaV1.2 channels,thereby changing the state of myocardium.However,there are still differences in the ability of CaM and CaMK? to regulate CaV1.2 in pathological myocardial hypertrophy,and the specific regulatory mechanism is not clear.Therefore,CaM and CaMK? are worth studying as drug targets.Objective:To observe the changes of Ca2+concentration in cardiac myocytes during pathological cardiac hypertrophy,and to detect the expression of CaV1.2 channels in cardiomyocytes during this process,to clarify the role of CaM and CaMK? in the regulation of CaV1.2 channels in pathological cardiac hypertrophy,and to explore the regulatory mechanism of CaM and CaMK? on CaV1.2 channels.Methods:1.The pathological cardiac hypertrophy model of SD rats was established by subcutaneous injection of isoproterenol?ISO?every 24 hours.2.The cardiac changes of SD rats were measured by heart weight?HW?and left ventricular weight?LVW?/body weight?BW?ratio.3.HE staining was used to detect the changes of cross-sectional area of cardiomyocytes and Masson staining was used to detect the changes of myocardial fibrosis.4.The expression of cardiac hypertrophy related protein was detected by Western blot.5.Co-IP test is used to detect the binding ability of CaM and CaMK? to CaV1.2 channel.6.Primary cardiomyocytes were induced by ISO to establish an in vitro model of pathological cardiac hypertrophy,and the effects of CaM and CaMK? on cardiomyoc ytes were detected by inhibitors.We used AIP to inhibit the expression of CaMK? and CMZ to inhibit the expression of CaM.7.The intracellular calcium concentration of cardiomyocytes was measured by flow cytometry??FCM??.Results:1.In vivo experiment,ISO was used to induce cardiac hypertrophy in SD rats.Compared with normal group,LVW/BW,HW/BW,cardiac cross-sectional area and myocardial fibrillation rate increased in ISO group.Western blotting showed that the protein expression levels of ANP,CaMK? and their phosphorylated form p-CaMK? increased in ISO group.However,the expression of CaM protein decreased,and there was no significant difference in the expression of CaV1.2 channel.We found that the binding ability of CaMK? to CaV1.2 channel in ISO group was higher than that in normal group,while the binding ability of CaM was decreased in ISO group.2.In the experiment in vitro,we found that the level of protein expression was consistent with that in vivo by Western blotting.Flow cytometry showed that ISO stimulation increased the activity of CaV1.2 channel and intracellular calcium concentration.3.In vitro experiments,we found that the expression of ANP,CaMK? and their phosphorylated form p-CaMK? in ISO group decreased after adding AIP.The expression of HDAC4,p-HDAC and MEF2C in AIP group also decreased,but no significant effect was found after adding CMZ.Conclusions:1.In the rat cardiac hypertrophy model,the expression of CaMK? in cardiomyocytes increased and the expressio n of CaM decreased;the binding capacity of CaMK? and CaV1.2 channels increased,while the binding capacity of CaM decreased.2.In the model of cardiomyocyte hypertrophy in neonatal rats,the changes of CaMK? and CaM were consistent with in vivo experiments.3.In the model of cardiomyocyte hypertrophy in neonatal rats,the increase of calcium ion concentration in cardiomyocytes may be due to the change in the binding capacity of CaM and CaMK? to CaV1.2.4.In the model of neonatal rat cardiomyocyte hypertrophy,AIP decreased the expression of ANP,CaMK? and p-CaMK?;meanwhile,the expression of HDAC4,p-HDAC and MEF2C also decreased;however,CMZ did not find any significant effect.5.CaM and CaMK? have different degrees of regulation of CaV1.2channel.Compared with CaM,CaMK? may be a more important drug target to reverse myocardial hypertrophy.
Keywords/Search Tags:Pathological cardiac hypertrophy, Ca_V1.2, calmodulin(CaM), Ca2+/calmodulin-dependent protein kinase ??CaMK??, autocamtide-2-related inhibitory peptide(AIP), Calmidazolium chloride(CMZ)
PDF Full Text Request
Related items